Synthesis, docking and evaluation of novel fused pyrimidine compounds as possible lead compounds with antibacterial and antitumor activities.
作者:Rami Y. Morjan、Amany F. El-Hallaq、Jannat N. Azarah、Ihab M. Almasri、Mazen M. Alzaharna、Mariam R. Al-Reefi、Ian Beadham、Omar S. Abu-Teim、Abdelraouf A. Elmanama、Adel M. Awadallah、James Raftery、John M. Gardiner
DOI:10.1016/j.molstruc.2023.135754
日期:2023.9
2-a]pyrimidine derivatives, or regioisomeric hydrazonamide adducts. The compounds were evaluated for antibacterial and anticancer activities. Screening against E. Coli, P. aeruginosa, S. aureus, S. epidermidis, B. subtilis and K. rhizophila did identify several different compound types with MIC of 0.1-0.4 mg/mL. Anticancer evaluation against a HeLa cell line identified one imidazo[1,2-a]pyrimidine lead
一系列亚肼酰氯与取代的氨基嘧啶的反应在大多数情况下提供了良好的选择性,导致形成新的咪唑并 [1,2-a] 嘧啶衍生物或区域异构的亚肼加合物。评估了这些化合物的抗菌和抗癌活性。针对大肠杆菌、铜绿假单胞菌、金黄色葡萄球菌、表皮葡萄球菌、枯草芽孢杆菌和K. rhizophila 的筛选确实鉴定出几种不同的化合物类型,MIC 为 0.1-0.4 mg/mL。针对 HeLa 细胞系的抗癌评估确定了一种咪唑并 [1,2-a] 嘧啶先导物。计算机模拟目标捕捞分析表明三个可能的高价值蛋白质目标,Tankyrase-2 (Tank-2)、细胞周期蛋白依赖性激酶 (CDK2) 和表皮生长因子酪氨酸激酶受体 (EGFR),模型适合共结晶的已知配体。这为进一步研究分子靶点和潜在的 SAR 活性开发提供了一个新的结构家族线索。